No Data
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 31%
ADC Therapeutics SA's (NYSE:ADCT) Institutional Investors Lost 18% Over the Past Week but Have Profited From Longer-term Gains
ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript Summary
ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why